Seaside Therapeutics Discontinues Arbaclofen (STX209) Extension Study

Published May 31, 2013 in The Boston Globe

Seaside Therapeutics has discontinued their extension study of Arbaclofen (STX209), a drug that showed promise in treating social impairment related to Fragile X syndrome.

http://www.bostonglobe.com/business/2013/05/30/cambridge-firm-autism-drug-fails-test-families-upset/mTOjxYyd67TI4jzg19K1iN/story.html

Filed under: , , , , , , ,